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Autophagy is a catabolic process that produces energy through lysosomal degradation of intracellular 
organelles.  Autophagy functions as a cytoprotective factor under physiological conditions such as 
nutrient deprivation,  hypoxia,  and interruption of growth factors.  On the other hand,  infection with 
pathogenic viruses and bacteria also induces autophagy in infected cells.  Oncolytic virotherapy with 
replication-competent viruses is thus a promising strategy to induce tumor-speciﬁc cell death.  
Oncolytic adenoviruses induce autophagy and subsequently contribute to cell death rather than cell 
survival in tumor cells.  We previously developed a telomerase-speciﬁc replication-competent oncolytic 
adenovirus,  OBP-301,  which induces cell lysis in tumor cells with telomerase activities.  OBP-301-
mediated cytopathic activity is signiﬁcantly associated with induction of autophagy biomarkers.  In this 
review,  we focus on the tumor-suppressive role and molecular basis of autophagic machinery induced 
by oncolytic adenoviruses.  Addition of tumor-speciﬁc promoters and modiﬁcation of the ﬁber knob of 
adenoviruses supports the oncolytic adenovirus-mediated autophagic cell death.  Autophagy is cooper-
atively regulated by the E1-dependent activation pathway,  E4-dependent inhibitory pathway,  and 
microRNA-dependent ﬁne-tuning.  Thus,  future exploration of the functional role and molecular 
mechanisms underlying oncolytic adenovirus-induced autophagy would provide novel insights and 
improve the therapeutic potential of oncolytic adenoviruses.
Key words: oncolytic adenovirus,  autophagy,  E2F1,  microRNA
utophagy is a catabolic process that produces 
energy through the lysosomal degradation of 
cytoplasmic organelles in autophagosomes [1].  
Physiological conditions such as nutrient deprivation 
[2],  hypoxia [3],  and abrogation of growth signaling 
[4] induce autophagy as a cytoprotective function.  On 
the other hand,  infection with pathogenic viruses and 
bacteria can also activate the autophagic machinery in 
infected cells [5,  6].  Virus-mediated autophagy func-
tions as an antiviral defense to eliminate viral compo-
nents in the innate immune system and as virus repli-
cation machinery to produce virions in the viral life 
cycle [5].  Oncolytic virotherapy with replication-
competent oncolytic viruses is a promising antitumor 
strategy to induce tumor-speciﬁc cell death [7].  
Among the oncolytic viruses,  oncolytic adenoviruses 
frequently induce autophagy and consequently contrib-
ute to cell death in tumor cells [8-10].  We previously 
generated a telomerase-speciﬁc,  replication-competent 
oncolytic adenovirus,  OBP-301,  which drives the 
adenoviral E1A and E1B genes under the control of the 
A
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human telomerase reverse transcriptase (hTERT) 
promoter for tumor-speciﬁc virus replication and 
induces oncolytic cell death in tumor cells with telom-
erase activities [11].  OBP-301 induces autophagy-
related cell death primarily in tumor cells [12,  13].  
To enhance the antitumor eﬀect of OBP-301,  we 
generated an armed OBP-301 variant (OBP-702) that 
expresses the tumor suppressor p53 gene.  OBP-702 
exhibits a more profound antitumor eﬀect in associa-
tion with autophagic and apoptotic cell death than 
OBP-301 [14].  Interestingly,  we found that the 
E1A-mediated microRNA (miRNA) signaling pathways 
were involved in the OBP-301- and OBP-702-mediated 
autophagic death of tumor cells [13,  14].  In the pres-
ent review,  we focus on the tumor-suppressive role of 
autophagy induced by oncolytic adenoviruses and the 
molecular mechanisms underlying the oncolytic adeno-
virus-induced autophagic cell death of tumor cells.
Tumor-Suppressive Role of Oncolytic 
Adenovirus-Induced Autophagy
　 Recent evidence in oncolytic virotherapy has shown 
that autophagy induction is associated with both cell 
death and cell survival in tumor cells infected with 
oncolytic adenoviruses (Table 1).  Most oncolytic ade-
noviruses induce autophagy and subsequently contrib-
ute to cell death rather than cell survival in tumor 
cells.  For example,  a conditionally replicating onco-
lytic adenovirus,  hTERT-Ad,  which contains a 255-
bp hTERT promoter fragment in the E1A promoter 
region for tumor-speciﬁc virus replication,  induces 
autophagic cell death in malignant brain tumor cells 
[8].  Our hTERT promoter-driven oncolytic adenovi-
rus,  OBP-301,  which contains a 455-bp hTERT 
promoter,  also induces autophagic cell death in tumor 
cells with telomerase activities [12,  13].  An RGD 
ﬁber‒modiﬁed OBP-301 variant (OBP-405) and a p53-
expressing OBP-301 variant (OBP-702) also induce 
more profound autophagic cell death than OBP-301 in 
malignant brain tumor cells [15] and mesenchymal 
tumor cells [14],  respectively.  Tumor-speciﬁc sur-
vivin promoter-driven oncolytic adenoviruses,  CRAd-
S-pk7 and CRAd-S-RGD,  which contain modiﬁed ﬁber 
knobs with PK7 and RGD motifs,  respectively,  also 
induce autophagic cell death in malignant brain tumor 
cells [10,  16].  In contrast,  an oncolytic adenovirus,  
Delta-24-RGD,  which lacks 24 bps (919-943) in the 
E1A region that binds to tumor suppressor retino-
blastoma (Rb) protein and contains RGD-modiﬁed ﬁber 
knobs,  induces autophagic cell death in malignant 
brain tumor cells [9,  17-19].  Human chorionic 
gonadotropin (hCG)-expressing oncolytic adenovirus 
Ad5/3∆24hCG,  which lacks a 24-bp segment (919-
334 Acta Med.  Okayama　Vol.  67,  No.  6Tazawa et al.
Table 1　 Role of autophagy induced by oncolytic adenoviruses
Oncolytic
adenovirus E1 Promoter E1A region E1B region Fiber knob Transgene
Function of
autophagy
hTERT-Ad hTERT ＋ ＋ wild-type － Cell death
OBP-301 hTERT ＋ ＋ wild-type － Cell death
OBP-301 hTERT ＋ ＋ wild-type － Cell death
OBP-405 hTERT ＋ ＋ RGD － Cell death
OBP-702 hTERT ＋ ＋ wild-type p53 Cell death
CRAd-S-pk7 Survivin ＋ ＋ PK7 － Cell death
CRAd-S-RGD Survivin ＋ ＋ RGD － Cell death
Delta-24-RGD wild-type del (919-943) ＋ RGD － Cell death
Delta-24-RGD wild-type del (919-943) ＋ RGD － Cell death
Delta-24-RGD wild-type del (919-943) ＋ RGD － Cell death
Delta-24-RGD wild-type del (919-943) ＋ RGD － Cell death
Ad5/3∆24hCG wild-type del (919-943) ＋ Ad3 hCG Cell death
dl922-947 wild-type del (922-947) ＋ wild-type － Cell survival
dl922-947 wild-type del (922-947) ＋ wild-type － Cell survival
hTERT,  human telomerase reverse transcriptase; RGD,  arginine-glycine-aspartate motif; PK7,  polylysine motif; hCG,  human chorionic 
gonadotropin; LC3,  microtubule-associated protein 1 light chain 3; AVO,  acidic vesicular organelle; Atg5,  autophagy-related 5; mTOR,  
mechanistic target of rapamycin; EGFR,  epidermal growth factor receptor; FADD,  Fas-associated via death domain; DRAM,  DNA-
damage regulated autophagy modulator.
943) of the E1A region and contains Ad5/3-modiﬁed 
ﬁber,  also induces autophagic cell death in human 
cancer cells [20].  However,  one type of oncolytic 
adenovirus,  dl922-947,  induces autophagy as a cyto-
protective function [21,  22].  A 24-bp segment (922-
947) of the E1A region is deleted in dl922-947; this 
deleted area is similar to the 24-bp deletion (919-943) 
in the E1A region of Delta-24-RGD.  However,  infec-
tion with dl922-947 induces autophagy as a cell-sur-
vival mechanism in ovarian cancer cells [21] and 
brain tumor cells [22].  The relationship between 
oncolytic adenoviruses and the function of autophagy 
is summarized in Table 1.  Oncolytic adenoviruses that 
induce autophagic cell death have tumor-speciﬁc pro-
moters for promoting viral replication and/or modiﬁed 
ﬁber knobs for enhancing virus infection,  whereas only 
dl922-947,  which induces cytoprotective autophagy,  
possesses both the wild-type E1 promoter and wild-
type ﬁber knobs.  These ﬁndings suggest that oncolytic 
adenoviruses with tumor-speciﬁc promoters and ﬁber 
modiﬁcations induce a greater amount of autophagy 
through the enhancement of viral replication and infec-
tion eﬃciency than wild-type adenovirus,  probably 
resulting in cell death rather than cell survival in 
tumor cells.
Biomarkers for Oncolytic Adenovirus-
Mediated Autophagy
　 When tumor cells are infected with oncolytic aden-
oviruses,  the modulation of autophagy-related marker 
proteins,  such as autophagy-related 5 (Atg5) [23],  
microtubule-associated protein 1 light chain 3 (LC3) 
[24],  and p62 [25],  is observed in the infected tumor 
cells (Table 1 and Fig.  1).  After infection with onco-
lytic adenoviruses,  Atg5 expression is upregulated 
following viral replication in the infected tumor cells 
[9].  Atg5 is conjugated with Atg12 to form the Atg5-
Atg12 complex,  which accumulates in the isolation 
membrane derived from the phagophore.  The long 
form of LC3-I is then converted to the short form of 
LC3-II.  LC3-II,  p62,  and intracellular organelles 
cooperatively bind to the isolation membrane contain-
ing the Atg5-Atg12 complex.  Autophagosomes fuse 
with lysosomes to become autolysosomes,  which are 
acidic vesicular organelles (AVOs) in which p62 and 
intracellular organelles are degraded.  Thus,  oncolytic 
adenovirus-induced autophagy can be conﬁrmed by 
detecting changes in autophagy-related biomarkers,  
including Atg5 upregulation [9,  13,  14,  17,  18],  
LC3-II upregulation [8,  9,  13-19,  22],  p62 down-
regulation [13,  14,  18,  19,  22],  and formation of 
cytoplasmic AVO [8-10,  12,  15-22].  Many oncolytic 
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Table 1　 Continued from the opposite page
Autophagy-related markers Autophagy-inducing factors References
LC3-II↑, AVO↑ Suppression of mTOR-p70S6K pathway Ito et al. [8]
AVO↑ Endo et al. [12]
LC3-II↑, Atg5↑, p62↓ E2F1-miR-7-EGFR pathway Tazawa et al. [13]
LC3-II↑,  AVO↑ Rapamycin (mTOR inhibitor) Yokoyama et al. [15]
LC3-II↑, Atg5↑, p62↓ E2F1-miR-93/106b-p21 & p53-DRAM pathways Hasei et al. [14]
LC3-II↑,  AVO↑ Ulasov et al. [16]
AVO↑ Beclin-1 Ulasov et al. [10]
LC3-II↑,  Atg5↑,  AVO↑ Jiang et al. [9]
LC3-II↑, Atg5↑, AVO↑ Everolimus (mTOR inhibitor) Alonso et al. [17]
LC3-II↑,  Atg5↑,  p62↓,  AVO↑ FADD/Caspase-8 pathway Jiang et al. [18]
LC3-II↑, p62↓, AVO↑ E1B19K-Beclin-1 complex Piya et al. [19]
AVO↑ Suppression of Mre11 Rajecki et al. [20]
AVO↑ Baird et al. [21]
LC3-II↑,  p62↓,  AVO↑ Botta et al. [22]
　
　
　
adenoviruses induce these autophagy-related markers 
in tumor cells (Table 1).
Mechanism of Oncolytic Adenovirus-Mediated 
Autophagy Induction
　 With respect to the molecular mechanism of the 
oncolytic adenovirus-mediated autophagy induction,  
adenoviral DNA-derived proteins,  including E1A,  
E1B,  and E4,  function as pro-autophagic and anti-
autophagic factors.  The E1A and E1B proteins 
mainly act as autophagy-inducing factors (Fig.  2).  In 
fact,  when 3 types of adenovirus vectors with diﬀer-
ent E1A and E1B regions,  i.e.,  the wild-type adenovi-
rus serotype 5 (Ad5),  E1B-deleted Adhz60,  and E1A- 
and E1B-deleted AdlacZ,  were compared with respect 
to their induction of autophagy in human tumor cells,  
Ad5 induced a higher level of autophagy than E1B-
deleted Adhz60,  and E1A- and E1B-deleted AdlacZ 
hardly induced autophagy [26],  suggesting the critical 
role of E1A and E1B in adenovirus-mediated autophagy 
induction.  Adenoviral E1A protein binds to tumor 
suppressor Rb protein,  which results in the activation 
of transcription factor E2F1 [27].  E2F1 activation 
induces autophagy through the upregulation of 
autophagy-related markers,  such as Atg5 and LC3,  in 
a transactivation-dependent and a transactivation-
independent manner [28,  29].  E1A-mediated E2F1 
upregulation may be mainly involved in the upregula-
tion of Atg5 and LC3-II after adenovirus infection.  In 
contrast,  adenoviral E1B protein interacts with pro-
autophagic Beclin1 through dissociation of the 
Beclin1-B cell/CLL lymphoma 2 (BCL2) complex,  
contributing to the induction of Beclin1-dependent 
autophagy [19].  E1B protein has also been suggested 
to induce autophagy through the inhibition of Mre11 
activity and dissociation of the Mre11-Rad50-NBS1 
complex,  contributing to the enhancement of radio-
sensitivity in human cancer cells [20,  30].  E1B may 
act mainly to support the E1A-mediated autophagy 
induction.  Moreover,  oncolytic adenovirus-induced 
autophagy may be enhanced by activation of the Fas-
associated via death domain (FADD)/caspase-8 signal-
ing pathway [18] and result in autophagic cell death 
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Fig. 1　 Schematic diagram of oncolytic adenovirus-mediated autophagy induction.  In tumor cells infected with oncolytic adenovirus,  
Atg5 expression is upregulated following viral replication.  The Atg5-Atg12 complex binds to the isolation membrane.  After conversion from 
LC3-I to LC3-II,  LC3-II,  p62,  and intracellular organelles cooperatively accumulate in the isolation membrane,  resulting in the formation of 
autophagosomes,  which fuse with lysosomes to form autolysosomes,  in which the p62-binding cytoplasmic organelle is degraded under the 
acidic condition and p62 expression is decreased.
through interaction with Atg5 and FADD [31].  In 
contrast,  the adenoviral E4 protein inhibits autophagy.  
E4 protein activates the mammalian target of rapamy-
cin (mTOR) signaling pathway [32],  which suppresses 
autophagy through suppression of unc-51-like autophagy 
activating kinase 1 (ULK1) activity by phosphoryla-
tion [33].  In fact,  E4 protein inhibits the oncolytic 
potential of the E1B-55K-deleted oncolytic adenovirus 
ONYX-015 through activation of the mTOR signaling 
pathway [34].  Suppression of the mTOR signaling 
pathway by rapamycin and everolimus enhances the 
autophagic cell death induced by oncolytic adenovi-
ruses (Table 1).  Thus,  oncolytic adenoviruses may 
strictly induce autophagy through regulation of the 
E1-dependent activation signaling pathway and the 
E4-dependent inhibitory signaling pathway.
Small Noncoding RNAs Regulated by Oncolytic 
Adenovirus
　 Infection with wild-type Ad5 regulates 2 diﬀerent 
types of small noncoding RNAs in the infected cells,  
viral miRNAs (mivaRNAs) and cellular miRNAs,  
which are respectively derived from virus-associated 
RNA (VA RNA) and cellular primary miRNA tran-
scripts (Fig.  3) [35].  Recently,  these 2 types of small 
noncoding RNAs have been suggested to be involved in 
antiviral defense and viral replication.  VA RNAs 
consist of 2 types of 160-nucleotide-noncoding RNAs,  
VA RNAI and VA RNAII,  which are transcribed by 
cellular RNA polymerase III from the adenoviral 
genome.  VA RNA induces the expression of type I 
interferon (IFN),  which is associated with innate 
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Fig. 2　 Schematic diagram of the molecular mechanism of onco-
lytic adenovirus-mediated autophagy induction.  Oncolytic adenovi-
rus induces the accumulation of adenoviral DNA-derived E1A,  E1B,  
and E4 proteins.  E1A protein upregulates E2F1 expression by sup-
pressing Rb activity.  E1B protein upregulates Beclin1 expression 
through the dissociation of the Beclin1-BCL2 complex.  In contrast,  
E4 protein downregulates ULK1 expression by activating the mTOR 
signaling pathway.  E1A and E1B proteins activate,  but E4 protein 
inhibits,  autophagy in association with Atg5 upregulation,  LC3-II 
upregulation,  and p62 downregulation.  Moreover,  oncolytic adeno-
virus-mediated autophagy can be enhanced by caspase-8 (Casp8) 
activation.
Oncolytic
adenovirus
mivaRNA miRNA
Viral
translation
Viral
replication
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E1AVA RNA
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Fig. 3　 Schematic diagram of antiviral and proviral processes 
regulated by small noncoding RNAs.  When infected with oncolytic 
adenovirus,  two types of small noncoding RNAs,  viral microRNA 
(mivaRNA) and cellular microRNA (miRNA),  are induced by virus-
associated RNA (VA-RNA) and E1A,  respectively.  VA RNA regu-
lates antiviral defense and viral translation through the RIG-I-IPS-1-
IFN signaling pathway and mivaRNA-PKR-eIF-2 signaling pathway,  
respectively.  E1A regulates viral replication and autophagy through 
the miRNA-p300-Myc signaling pathway.
immune responses [36-38].  In terms of the molecular 
mechanism of VA RNA-mediated IFN induction,  the 
involvement of IFN-β promoter stimulator-1 (IPS-1) 
and retinoic acid-inducible gene I (RIG-I) has been 
suggested [37-39],  whereas the role of VA RNA-
derived mivaRNAs remains to be elucidated.  VA RNA 
further activates the eukaryotic translation initiation 
factor 2α (eIF-2) through suppression of protein 
kinase R (PKR),  contributing to the translation of 
viral mRNA [40-42].  However,  a recent report has 
suggested that VA RNA-derived mivaRNAs are not 
involved in adenovirus-mediated cell lysis [43].  In 
contrast to this report,  evidence also supports the 
utility of VA RNA-deleted oncolytic adenovirus to 
induce more profound antitumor eﬀects in tumor cells 
and lower cytotoxicity in normal cells than wild-type 
adenovirus [44-46].  In contrast,  adenoviral E1A 
protein modulates the expression of cellular miRNAs 
in tumor cells (Fig.  3) [47].  We also demonstrated 
the modulation of cellular miRNAs in oncolytic adeno-
virus-infected tumor cells [13,  14].  These miRNAs 
are mainly transcribed by RNA polymerase II from the 
cellular DNA genome.  E1A protein is necessary for 
viral replication because E1A-deleted adenovirus lacks 
the ability to replicate.  E1A protein induces DNA 
synthesis and viral replication followed by S phase 
entry through upregulation of c-Myc [48-50],  which 
is caused by suppression of the p300 transcriptional 
co-activator through an unknown mechanism [51,  52].  
Since miR-132 regulates the antiviral defense and 
viral replication through suppression of p300 after 
infection with other types of viruses [53,  54],  viral 
replication of oncolytic adenovirus may also be regu-
lated by an E1A-dependent miRNA network through 
suppression of p300 (Fig.  3).  Recent reports have 
suggested that both p300 knockdown [55] and c-Myc 
overexpression [56] induce autophagy; thus,  viral 
replication induced by p300 downregulation and c-Myc 
upregulation may contribute to autophagy induction.  
These ﬁndings suggest that VA RNA-derived mivaR-
NAs mainly induce antiviral defense in the innate 
immune response,  whereas E1A protein supports viral 
replication in the adaptive immune response.  E1A-
mediated viral replication may further promote the 
autophagic machinery.  Moreover,  VA RNA-derived 
mivaRNAs and cellular miRNAs competitively inhibit 
the RNAi machinery [57-59],  whereas E1A protein 
suppresses the accumulation of VA RNAs through 
suppression of RNA polymerase III [60].  Therefore,  
the crosstalk between VA RNA and E1A protein may 
ﬁnally decide the cellular fate with respect to cell 
survival or cell death in oncolytic adenovirus-infected 
cells.
E2F1-Regulated miRNAs in Oncolytic 
Adenovirus-Induced Cell Death
　 Adenovirus infection activates E2F1 expression 
through the E1A-dependent suppression of Rb protein 
[27].  Recent evidence in tumor biology has shown the 
presence of the E2F1-regulated small noncoding miR-
NAs as tumor-suppressive factors [61] or oncogenic 
factors [62].  The crosstalk between E2F1 and the 
E2F1-regulated miRNA network has been suggested 
to be critical for determining the prosurvival and 
antiproliferative eﬀects of E2F1 in cancer [63].  We 
recently demonstrated the involvement of E2F1-
regulated miRNAs in oncolytic adenovirus-induced cell 
death (Fig.  4) [13,  14].  When human cancer cells 
were infected with the hTERT promoter-driven onco-
lytic adenovirus OBP-301,  miR-7 expression was 
upregulated in a time- and dose-dependent manner 
[13].  Overexpression of exogenous E2F1 induced 
miR-7 expression,  whereas pretreatment with E2F1 
siRNA attenuated the OBP-301-induced miR-7 
upregulation in human cancer cells,  suggesting the 
E2F1-dependent regulation of miR-7 expression.  
Interestingly,  ectopic expression of exogenous miR-7 
induced autophagy-related cell death through suppres-
sion of oncogenic epidermal growth factor receptor 
(EGFR) [13].  Another report also supports that sup-
pression of EGFR expression by EGFR siRNA induces 
autophagic cell death in human cancer cells [64].  The 
EGFR-downstream phosphatidylinositol 3ʼ-kinase 
-Akt-mTOR signaling pathway suppresses the 
autophagy machinery [65].  We reported that OBP-
702 in p53-expressing OBP-702-infected tumor cells 
suppressed the expression of p21,  which functions as 
both an anti-apoptotic [66] and anti-autophagic factor 
[67],  through upregulation of miR-93 and miR-106 
[14,  68].  miR-93/106-mediated p21 downregulation 
enhanced the apoptotic and autophagic cell deaths 
induced by p53-mediated pro-apoptotic BCL2-associated 
X protein (BAX) and pro-autophagic DNA-damage 
regulated autophagy modulator (DRAM) proteins 
[14].  miR-93 and miR-106 are upregulated by E2F1 
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and suppress the expression of p21 [69].  We recently 
observed that,  in human tumor cells co-treated with 
OBP-301 and chemotherapy,  OBP-301 downregulated 
the expression of the anti-apoptotic BCL2 family 
myeloid cell leukemia sequence 1 (MCL1) through 
upregulation of miR-15 and miR-16,  resulting in the 
enhancement of chemotherapy-induced apoptotic cell 
death (our unpublished data).  Other types of oncolytic 
adenoviruses downregulate the expression of MCL1 in 
infected tumor cells [70,  71].  Moreover,  miR-15 and 
miR-16 can be upregulated by E2F1 [72] and sup-
press the expression of MCL1 [73].  A recent report 
also supports the modulation of cellular miRNAs in 
adenoviral E1A-overexpressed human cancer cells 
[47].  Downregulation of miR-520h by E1A activation 
was associated with E1A-dependent antitumor eﬀects 
[47].  In this report,  more interestingly,  some E2F1-
inducible miRNAs (miR-92,  miR-18,  miR-15,  miR-93,  
miR-25) were upregulated in the E1A-expressing 
human cancer cells [47],  which was consistent with 
our recent experimental observations (Fig.  4).  These 
ﬁndings suggest that the E2F1-regulated miRNA 
network is a critical signaling pathway for ﬁne-tuning 
the oncolytic adenovirus-induced autophagic and apop-
totic cell deaths through the suppression of anti-
autophagic and anti-apoptotic factors.
Conclusion
　 Oncolytic virotherapy is a promising antitumor 
339Adenovirus-Mediated Autophagy InductionDecember 2013
Autophagy
E2F1
OBP-301
OBP-702
miR-93
miR-106
E1A
miR-15
miR-16 miR-7
Apoptosis
E2F1 E2F1
p21MCL1 EGFR
Cell 
Death
E1A E1A
BAX DRAM
p53 p53
OBP-702 OBP-702
Fig. 4　 Schematic diagram of E1A-dependent cell death pathways through the E2F1-regulated miRNA network.  Oncolytic adenoviruses,  
OBP-301 and OBP-702,  induce E1A-dependent cell death pathways through regulation of the E2F1-inducible miRNA network.  E2F1-
inducible miRNAs (miR-7,  miR-15,  miR-16,  miR-93,  miR-106) induce apoptotic and autophagic cell death through suppression of anti-
apoptotic and anti-autophagic factors (MCL1,  p21,  EGFR).  Overexpression of tumor suppressor p53 also induces apoptotic and 
autophagic cell death via upregulation of p53-downstream targets,  BAX and DRAM,  respectively,  in OBP-702-infected tumor cells.
strategy for eliminating tumor cells without adversely 
aﬀecting normal cells.  Various types of oncolytic 
adenoviruses have been developed,  and these viruses 
mainly induce autophagy-related cell death in tumor 
cells.  However,  the molecular mechanisms underlying 
the oncolytic adenovirus-induced autophagic cell death 
remains unclear.  Some adenoviral proteins,  including 
E1A,  E1B,  and E4,  have been suggested to be impli-
cated in the regulation of autophagic machinery.  
Moreover,  following E1A accumulation,  the E2F1-
regulated microRNA network may be involved in ﬁne-
tuning of the oncolytic cell death associated with 
autophagy.  An exploration of the functional role and 
molecular basis of oncolytic adenovirus-mediated 
autophagy induction would help to improve the thera-
peutic potential of oncolytic virotherapy.
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